GLI1 and hepatocellular carcinoma: Targeting Gli with arsenic trioxide (ATO) in has been assessed in phase II clinical trials in treating patients with metastatic liver cancer (NCT00128596), and advanced primary carcinoma of the liver (NCT00582400).